Medical mycology and fungal immunology: New research perspectives addressing a major world health challenge

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 371, Issue 1709, 2016, Pages

  Gow, Neil A R ^a   Netea, Mihai G ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fungal cell wall; Fungal infection; Genetic susceptibility; Immune recognition; Microbiome

Indexed keywords

DRUG DEVELOPMENT; EPIDEMIOLOGY; FUNGAL DISEASE; FUNGUS; GLOBAL PERSPECTIVE; HEALTH CARE; IMMUNE SYSTEM; IMMUNITY; MEDICAL GEOGRAPHY; MORTALITY; PATHOLOGY; PUBLIC HEALTH; VACCINE;

FUNGI;

FUNGUS; GLOBAL HEALTH; IMMUNOLOGY; MICROBIOLOGY; MYCOLOGY; MYCOSIS; RESEARCH;

FUNGI; GLOBAL HEALTH; MYCOLOGY; MYCOSES; RESEARCH;

EID: 84992453056     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2015.0462     Document Type: Review

References (92)

1. Casadevall A, Pirofski LA. 2003 The damageresponse framework of microbial pathogenesis. Nat. Rev. Microbiol. 1, 17–24. (doi:10.1038/nrmicro732)
2. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. 2012 Hidden killers: human fungal infections. Sci. Transl. Med. 19, 165rv13. (doi:10.1126/scitranslmed.3004404)
3. Netea MG, Brown GD, Kullberg BJ, Gow NAR. 2008 An integrated model of the recognition of Candida albicans by the innate immune system. Nat. Rev. Microbiol. 6, 67–78. (doi:10.1038/nrmicro1815)
4. Gow NAR, van de Veerdonk FL, Brown AJ, Netea MG. 2011 Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat. Rev. Microbiol. 10, 112–122. (doi:10.1038/nrmicro2711)
5. Erwig LP, Gow NAR. 2016 Interactions of fungal pathogens with phagocytes. Nat. Rev. Microbiol. 14, 163–176. (doi:10.1038/nrmicro.2015.21)
6. Moyes DL et al. 2016 Candidalysin is a fungal peptide toxin critical for mucosal infection. Nature 532, 64–68. (doi:10.1038/nature17625)
7. Hardison SE, Brown GD. 2012 C-type lectin receptors orchestrate antifungal immunity. Nat. Immunol. 13, 817–822. (doi:10.1038/ni.2369)
8. de Sousa MGT et al. 2011 Restoration of pattern recognition receptor costimulation to treat chromoblastomycosis, a chronic fungal infection of the skin. Cell Host Microbe 9, 436–443. (doi:10.1016/j.chom.2011.04.005)
9. De Sousa MGT, Belda W, Spina R, Lota PR, Valente NS, Brown GD, Craido PR, Bernardi G. 2014 Topical application of Imiquimod as a treatment for chromoblastomycosis. Clin. Infect. Dis. 58, 1734–1737. (doi:10.1093/cid/ciu168)
10. Wheeler RT, Fink GR. 2006 A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog. 2, e35. (doi:10.1371/journal.ppat.0020035)
11. Wheeler RT, Kombe D, Agarwala SD, Fink GR. 2008 Dynamic, morphotype-specific Candida albicans bglucan exposure during infection and drug treatment. PLoS Pathog. 4, e1000227. (doi:10.1371/journal.ppat.1000227)
12. Hall RA et al. 2013 The Mnn2 mannosyltransferase family modulates mannoprotein fibril length, immune recognition and virulence of Candida albicans. PLoS Pathog. 9, e1003276. (doi:10.1371/journal.ppat.1003276)
13. Hall RA, Gow NAR. 2013 Mannosylation in Candida albicans: role in cell wall function and immune recognition. Mol. Microbiol. 90, 1147–1161. (doi:10.1111/mmi.12426)
14. Dennehy KM et al. 2008 Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur. J. Immunol. 38, 500–506. (doi:10.1002/eji.200737741)
15. Wagener J et al. 2014 Fungal chitin dampens inflammation through IL-10 induction mediated by NOD2 and TLR9 activation. PLoS Pathog. 10, e1004050. (doi:10.1371/journal.ppat.1004050)
16. Nagatani K et al. 2012 Chitin microparticles for the control of intestinal inflammation. Inflamm. Bowel Dis. 18, 1698–1710. (doi:10.1002/ibd.22874)
17. Lee KK, MacCallum DM, Jacobsen MD, Walker LA, Odds FC, Gow NAR, Munro CA. 2012 Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob. Agents Chemother. 56, 208–217. (doi:10.1128/AAC.00683-11)
18. Walker LA, Lee KK, Munro CA, Gow NAR. 2015 Caspofungin treatment of Aspergillus fumigatus results in ChsG-dependent upregulation of chitin synthesis and the formation of chitin-rich microcolonies. Antimicrob. Agents Chemother. 59, 5932–5941. (doi:10.1128/AAC.00862-15)
19. Finnish-German APECED Consortium. 1997 An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat. Gen. 17, 399–403. (doi:10.1038/ng1297-399)
20. Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. 1990 Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N. Engl. J. Med. 322, 1829–1836. (doi:10.1056/NEJM199006283222601)
21. Kisand K et al. 2010 Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 207, 299–308. (doi:10.1084/jem.20091669)
22. Puel A et al. 2010 Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207, 291–297. (doi:10.1084/jem.20091983)
23. van de Veerdonk FL et al. 2011 STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N. Engl. J. Med. 365, 54–61. (doi:10.1056/NEJMoa1100102)
24. Liu L et al. 2011 Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 208, 1635–1648. (doi:10.1084/jem.20110958)
25. Puel A et al. 2011 Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332, 65–68. (doi:10.1126/science.1200439)
26. Davis SD, Schaller J, Wedgwood RJ. 1966 Job’s Syndrome. Recurrent, ‘cold’, staphylococcal abscesses. Lancet 287, 1013–1015. (doi:10.1016/S0140-6736(66)90119-X)
27. Holland SM et al. 2007 STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357, 1608–1619. (doi:10.1056/NEJMoa073687)
28. Minegishi Y et al. 2007 Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448, 1058–1062. (doi:10.1038/nature06096)
29. Engelhardt KR et al. 2009 Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J. Allergy Clin. Immunol. 124, 1289–1302.e4. (doi:10.1016/j.jaci.2009.10.038)
30. Minegishi Y et al. 2006 Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745–755. (doi:10.1016/j.immuni.2006.09.009)
31. de Beaucoudrey L et al. 2008 Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J. Exp. Med. 205, 1543–1550. (doi:10.1084/jem.20080321)
32. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, Fulcher DA, Tangye SG, Cook MC. 2008 Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 205, 1551–1557. (doi:10.1084/jem.20080218)
33. Milner JD et al. 2008 Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452, 773–776. (doi:10.1038/nature06764)
34. Winkelstein JA et al. 2000 Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine 79, 155–169. (idoi:10.1097/00005792-200005000-00003)
35. Matute JD et al. 2009 A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 114, 3309–3315. (doi:10.1182/blood-2009-07-231498)
36. Gallin JI et al. 2003 Itraconazole to prevent fungal infections in chronic granulomatous disease. N. Engl. J. Med. 348, 2416–2422. (doi:10.1056/NEJMoa021931)
37. Group TICGDCS. 1991 A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N. Engl. J. Med. 324, 509–516. (doi:10.1056/NEJM199102213240801)
38. Seger RA. 2010 Hematopoietic stem cell transplantation for chronic granulomatous disease. Immunol. Allerg. Clin. N. Am. 30, 195–208. (doi:10.1016/j.iac.2010.01.003)
39. Ott MG, Seger R, Stein S, Siler U, Hoelzer D, Grez M. 2007 Advances in the treatment of chronic granulomatous disease by gene therapy. Curr. Gene Ther. 7, 155–161. (doi:10.2174/156652307780859044)
40. Glocker EO et al. 2009 A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N. Engl. J. Med. 361, 1727–1735. (doi:10.1056/NEJMoa0810719)
41. Lanternier F et al. 2015 Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species-induced meningoencephalitis, colitis, or both. J. Allergy Clin. Immunol. 135, 1558–1568.e2. (doi:10.1016/j.jaci.2014.12.1930)
42. Ferwerda B et al. 2009 Human dectin-1 deficiency and mucocutaneous fungal infections. N. Engl. J. Med. 361, 1760–1767. (doi:10.1056/NEJMoa0901053)
43. Plantinga TS et al. 2009 Early stop polymorphism in human DECTIN-1 is associated with increased Candida colonization in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 49, 724–732. (doi:10.1086/604714)
44. Plantinga TS et al. 2010 Genetic variation of innate immune genes in HIV-infected African patients with or without oropharyngeal candidiasis. J. Acquir. Immune Defic. Syndr. 55, 87–94. (doi:10.1097/QAI.0b013e3181e53c64)
45. Plantinga TS et al. 2012 Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J. Infect. Dis. 205, 934–943. (doi:10.1093/infdis/jir867)
46. Nahum A, Dadi H, Bates A, Roifman CM. 2011 The L412F variant of Toll-like receptor 3 (TLR3) is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity. J. Allergy Clin. Immunol. 127, 528–531. (doi:10.1016/j.jaci.2010.09.031)
47. Johnson MD et al. 2012 Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. Clin. Infect. Dis. 54, 502–510. (doi:10.1093/cid/cir827)
48. Babula O, Lazdane G, Kroica J, Ledger WJ, Witkin SS. 2003 Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannosebinding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin. Infect. Dis. 37, 733–737. (doi:10.1086/377234)
49. Giraldo PC, Babula O, Goncalves AKS, Linhares IM, Amaral RL, Ledger WJ, Witkin SS. 2007 Mannosebinding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet. Gynecol. 109, 1123–1128. (doi:10.1097/01.AOG.0000260386.17555.a5)
50. van Till JW, Modderman PW, de Boer M, Hart MH, Beld MG, Boermeester MA. 2008 Mannose-binding lectin deficiency facilitates abdominal Candida infections in patients with secondary peritonitis. Clin. Vaccine Immunol. 15, 65–70. (doi:10.1128/CVI.00297-07)
51. Babula O, Lazdane G, Kroica J, Linhares IM, Ledger WJ, Witkin SS. 2005 Frequency of interleukin-4 (IL-4)-589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannosebinding lectin in women with recurrent vulvovaginal candidiasis. Clin. Infect. Dis. 40, 1258–1262. (doi:10.1086/429246)
52. Choi EH et al. 2003 Association between chronic disseminated candidiasis in adult acute leukemia and common IL4 promoter haplotypes. J. Infect. Dis. 187, 1153–1156. (doi:10.1086/368345)
53. Lev-Sagie A, Prus D, Linhares IM, Lavy Y, Ledger WJ, Witkin SS. 2009 Polymorphism in a gene coding for the inflammasome component NALP3 and recurrent vulvovaginal candidiasis in women with vulvar vestibulitis syndrome. Am. J. Obstet. Gynecol. 200, 303.e1–303.e6. (doi:10.1016/j.ajog.2008.10.039)
54. Jurevic RJ, Bai M, Chadwick RB, White TC, Dale BA 2003 Single-nucleotide polymorphisms (SNPs) in human b-defensin 1: high-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls. J. Clin. Microbiol. 41, 90–96. (doi:10.1128/JCM.41.1.90-96.2003)
55. Kumar V et al. 2014 Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. Nat. Commun. 5, 4675. (doi:10.1038/ncomms5675)
56. Van der Graaf CA, Netea MG, Morre SA, Den Heijer M, Verweij PE, Van der Meer JW, Kullberg BJ. 2006 Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur. Cytokine Netw. 17, 29–34.
57. Woehrle T, Du W, Goetz A, Hsu H-Y, Joos TO, Weiss M, Bauer U, Brueckner UB, Marion Schneider E. 2008 Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans. Cytokine 41, 322–329. (doi:10.1016/j.cyto.2007.12.006)
58. Morre SA, Murillo LS, Spaargaren J, Fennema HS, Pena AS. 2002 Role of the toll-like receptor 4 Asp299Gly polymorphism in susceptibility to Candida albicans infection. J. Infect. Dis. 186, 1377–1379. (doi:10.1086/344328)
59. Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV, Weinberg A, Sieg SF. 2007 Human b-defensin-3 activates professional antigenpresenting cells via Toll-like receptors 1 and 2. Proc. Natl Acad. Sci. USA 104, 18 631–18 635. (doi:10.1073/pnas.0702130104)
60. Hoover DM, Wu Z, Tucker K, Lu W, Lubkowski J. 2003 Antimicrobial characterization of human b-defensin 3 derivatives. Antimicrob. Agents Chemother. 47, 2804–2809. (doi:10.1128/AAC.47.9.2804-2809.2003)
61. Morahan G, Huang D, Wu M, Holt BJ, White GP, Kendall GE, Sly PD, Holt PG. 2002 Association of IL12B promoter polymorphism with severity of atopic and non-atopic asthma in children. Lancet 360, 455–459. (doi:10.1016/S0140-6736(02)09676-9)
62. Muller-Berghaus J, Kern K, Paschen A, Nguyen XD, Klüter H, Morahan G, Schadendorf D. 2004 Deficient IL-12p70 secretion by dendritic cells based on IL12B promoter genotype. Genes Immunol. 5, 431–434. (doi:10.1038/sj.gene.6364102)
63. Schaaf BM, Boehmke F, Esnaashari H, Seitzer U, Kothe H, Maass M, Zabel P, Dalhoff K. 2003 Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am. J. Respir. Crit. Care Med. 168, 476–480. (doi:10.1164/rccm.200210-1164OC)
64. Stanilova SA, Miteva LD, Karakolev ZT, Stefanov CS. 2006 Interleukin-10-1082 promoter polymorphism in association with cytokine production and sepsis susceptibility. Intens. Care Med. 32, 260–266. (doi:10.1007/s00134-005-0022-4)
65. Zeng L et al. 2009 Clinical relevance of the interleukin 10 promoter polymorphisms in Chinese Han patients with major trauma: genetic association studies. Crit. Care 13, R188. (doi:10.1186/cc8182)
66. Romani L, Mencacci A, Grohmann U, Mocci S, Mosci P, Puccetti P, Bistoni F. 1992 Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. J. Exp. Med. 176, 19–25. (doi:10.1084/jem.176.1.19)
67. Romani L, Puccetti P, Mencacci A, Cenci E, Spaccapelo R, Tonnetti L, Grohmann U, Bistoni F. 1994 Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J. Immunol. 152, 3514–3521.
68. Aydemir C, Onay H, Oguz SS, Ozdemir TR, Erdeve O, Ozkinay F, Dilmen U. 2011 Mannose-binding lectin codon 54 gene polymorphism in relation to risk of nosocomial invasive fungal infection in preterm neonates in the neonatal intensive care unit. J. Matern. Fetal Neonatal Med. 24, 1124–1127. (doi:10.3109/14767058.2010.536865)
69. Brouwer N, Dolman KM, van Houdt M, Sta M, Roos D, Kuijpers TW. 2008 Mannose-binding lectin (MBL) facilitates opsonophagocytosis of yeasts but not of bacteria despite MBL binding. J. Immunol. 180, 4124–4132. (doi:10.4049/jimmunol.180.6.4124)
70. van Asbeck EC, Hoepelman AI, Scharringa J, Herpers BL, Verhoef J. 2008 Mannose binding lectin plays a crucial role in innate immunity against yeast by enhanced complement activation and enhanced uptake of polymorphonuclear cells. BMC Microbiol. 8, 229. (doi:10.1186/1471-2180-8-229)
71. Rabeneck L, Crane MM, Risser JM, Lacke CE, Wray NP. 1993 A simple clinical staging system that predicts progression to AIDS using CD4 count, oral thrush, and night sweats. J. Gen. Intern. Med. 8, 5–9. (doi:10.1007/BF02600284)
72. Samaranayake LP, Holmstrup P. 1989 Oral candidiasis and human immunodeficiency virus infection. J. Oral Pathol. Med. 18, 554–564. (doi:10.1111/j.1600-0714.1989.tb01552.x)
73. Samaranayake LP. 1992 Oral mycoses in HIV infection. Oral Surg. Oral Med. Oral Pathol. 73, 171–180. (doi:10.1016/0030-4220(92)90191-R)
74. Pflughoeft KJ, Versalovic J. 2012 Human microbiome in health and disease. Annu. Rev. Pathol. Mech. Dis. 7, 99–122. (doi:10.1146/annurev-pathol-011811-132421)
75. Gunsalus K, Tornberg-Belanger SN, Matthan NR, Lichtenstein AH, Kumamoto CA. 2016 Manipulation of host diet to reduce gastrointestinal colonization by the opportunistic pathogen Candida albicans. mSphere 1, e00020-15. (doi:10.1128/mSphere.00020-15)
76. Kennedy MJ, Volz PA. 1985 Ecology of Candida albicans gut colonization: inhibition of Candida adhesion, colonization, and dissemination from the gastrointestinal tract by bacterial antagonism. Infect. Immun. 49, 654–663.
77. Noverr MC, Huffnagle GB. 2004 Regulation of Candida albicans morphogenesis by fatty acid metabolites. Infect. Immun. 72, 6206–6210. (doi:10.1128/IAI.72.11.6206–6210)
78. Hogan DA, Vik Å., Kolter R. 2004 A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol. Microbiol. 54, 1212–1223. (doi:10.1111/j.1365-2958.2004.04349)
79. Cruz MR, Graham CE, Gagliano BC, Lorenz MC, Garsin DA. 2013 Enterococcus faecalis inhibits hyphal morphogenesis and virulence of Candida albicans. Infect. Immun. 81, 189–200. (doi:10.1128/IAI.00914-12)
80. Jenkinson HF, Lala HC, Shepherd MG. 1990 Coaggregation of Streptococcus sanguis and other streptococci with Candida albicans. Infect. Immun. 58, 1429–1436.
81. Romani L, Zelante T, Palmieri M, Napolioni V, Picciolini M, Velardi A, Aversa F, Puccetti P. 2015 The cross-talk between opportunistic fungi and the mammalian host via microbiota’s metabolism. Semin. Immunopathol. 37, 163–171. (doi:10.1007/s00281-014-0464-2)
82. Oever JT, Netea MG. 2014 The bacteriome-mycobiome interaction and antifungal host defense. Eur. J. Immunol. 44, 3182–3191. (doi:10.1002/eji.201344405)
83. Kolwijck E, van de Veerdonk FL. 2014 The potential impact of the pulmonary microbiome on immunopathogenesis of Aspergillus-related lung disease. Eur. J. Immunol. 44, 3156–3165. (doi:10.1002/eji.201344404)
84. Trompette A et al. 2014 Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 20, 159–166. (doi:10.1038/nm.3444)
85. Zelante T et al. 2013 Tryptophan catabolites from microbiota engage Aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39, 372–385. (doi:10.1016/j.immuni.2013.08.003)
86. Smeekens SP et al. 2013 Skin microbiome imbalance in patients with STAT1/STAT3 defects impairs innate host defense responses. J. Innate Immun. 6, 253–262. (doi:10.1159/000351912)
87. Liu M-B, Xu S-R, He Y, Deng G-H, Sheng H-F, Huang X-M, Ouyang C-Y, Zhou H-W. 2013 Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis. PLoS ONE 8, e79812. (doi:10.1371/journal.pone.0079812)
88. Findley K et al. 2013 Topographic diversity of fungal and bacterial communities in human skin. Nature 498, 367–370. (doi:10.1038/nature12171)
89. Huffnagle GB, Noverr MC. 2013 The emerging world of the fungal microbiome. Trends Microbiol. 21, 334–341. (doi:10.1016/j.tim.2013.04.002)
90. Kim Y-G, Udayanga KGS, Totsuka N, Weinberg JB, Nuñez G, Shibuya A. 2014 Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE2. Cell Host Microbe 15, 95–102. (doi:10.1016/j.chom.2013.12.010)
91. Iliev ID et al. 2012 Interactions between commensal fungi and the C-type lectin receptor dectin-1 influence colitis. Science 336, 1314–1317. (doi:10.1126/science.1221789)
92. Mukherjee PK et al. 2014 Oral mycobiome analysis of HIV-infected patients: identification of Pichia as an antagonist of opportunistic fungi. PLoS Pathog. 10, e1003996. (doi:10.1371/journal.ppat.1003996)